Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.

Published

Journal Article

Experimental and epidemiological data support the potential activity of acetaminophen against ovarian cancer (OVCA). In this study, we sought to confirm the activity of acetaminophen in OVCA cell lines and to investigate the molecular basis of response. A total of 16 OVCA cell lines underwent pretreatment (baseline) genome-wide expression measurements and were then treated with and analyzed for acetaminophen sensitivity. Pearson's correlation analysis was performed to identify genes that were associated with OVCA acetaminophen response. The identified genes were subjected to pathway analysis, and the expression of each represented pathway was summarized using principal component analysis. OVCA acetaminophen response pathways were analyzed in 4 external clinico-genomic datasets from 820 women for associations with overall survival from OVCA. Acetaminophen exhibited antiproliferative activity against all tested OVCA cell lines, with half maximal inhibitory concentration values ranging from 63.2 to 403 µM. Pearson's correlation followed by biological pathway analysis identified 13 pathways to be associated with acetaminophen sensitivity (P<0.01). Associations were observed between patient survival from OVCA and expression of the following pathways: Development/angiotensin signaling via β-arrestin (P=0.04), protein folding and maturation/angiotensin system maturation (P=0.02), signal transduction/c-Jun N-terminal kinase (JNK) pathway (P=0.03) and androstenedione and testosterone biosynthesis and metabolism (P=0.02). We confirmed that acetaminophen was active against OVCA cells in vitro. Furthermore, we identified 4 molecular signaling pathways associated with acetaminophen response that may also affect overall survival in women with OVCA, including the JNK pathway, which has been previously implicated in the mechanism of action of acetaminophen and is predictive of decreased survival in women with OVCA.

Full Text

Duke Authors

Cited Authors

  • Bush, SH; Tollin, S; Marchion, DC; Xiong, Y; Abbasi, F; Ramirez, IJ; Zgheib, NB; Boac, B; Judson, PL; Chon, HS; Wenham, RM; Apte, SM; Cubitt, CL; Berglund, AE; Havrilesky, LJ; Lancaster, JM

Published Date

  • March 2016

Published In

Volume / Issue

  • 4 / 3

Start / End Page

  • 399 - 404

PubMed ID

  • 26998291

Pubmed Central ID

  • 26998291

International Standard Serial Number (ISSN)

  • 2049-9450

Digital Object Identifier (DOI)

  • 10.3892/mco.2016.725

Language

  • eng

Conference Location

  • England